Rapid induction of lung adenocarcinoma by fibroblast growth factor 9 signaling through FGF receptor 3

Yongjun Yin, Tomoko Betsuyaku, Joel R. Garbow, Jinbai Miao, Ramaswamy Govindan, David M. Ornitz

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Fibroblast growth factors (FGF) are expressed in many non-small cell lung carcinoma (NSCLC) primary tumors and derived cell lines, and mutations in FGF receptor 3 (FGFR3) have been identified in human lung adenocarcinoma. FGF9 has been implicated in the pathogenesis of NSCLC by synergizing with EGFR pathways or by providing an escape pathway mediating resistance to EGFR inhibition. To model pathogenic mechanisms mediated by FGF signals, we have established a mouse model in which FGF9 expression can be induced in adult lung epithelium. Here, we show that induced expression of FGF9 in adult lung leads to the rapid proliferation of distal airway epithelial cells that express the stem cell marker, Sca-1, and the proximal and distal epithelial markers, Sftpc and CC10, the rapid formation of Sftpc-positive adenocarcinomas, and eventual metastasis in some mice. Furthermore, we have identified FGFR3 as the obligate receptor mediating the FGF9 oncogenic signal. These results identify an FGF9-FGFR3 signal as a primary oncogenic pathway for lung adenocarcinoma and suggest that this pathway could be exploited for customized therapeutic applications for both primary tumors and those that have acquired resistance to inhibition of other signaling pathways.

Original languageEnglish
Pages (from-to)5730-5741
Number of pages12
JournalCancer Research
Volume73
Issue number18
DOIs
Publication statusPublished - 2013 Sep 15

Fingerprint

Fibroblast Growth Factor 9
Receptor, Fibroblast Growth Factor, Type 3
Fibroblast Growth Factor Receptors
Fibroblast Growth Factors
Non-Small Cell Lung Carcinoma
Lung
Tumor Cell Line
Adenocarcinoma
Stem Cells
Epithelium
Epithelial Cells
Neoplasm Metastasis
Mutation
Neoplasms
Adenocarcinoma of lung
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yin, Y., Betsuyaku, T., Garbow, J. R., Miao, J., Govindan, R., & Ornitz, D. M. (2013). Rapid induction of lung adenocarcinoma by fibroblast growth factor 9 signaling through FGF receptor 3. Cancer Research, 73(18), 5730-5741. https://doi.org/10.1158/0008-5472.CAN-13-0495

Rapid induction of lung adenocarcinoma by fibroblast growth factor 9 signaling through FGF receptor 3. / Yin, Yongjun; Betsuyaku, Tomoko; Garbow, Joel R.; Miao, Jinbai; Govindan, Ramaswamy; Ornitz, David M.

In: Cancer Research, Vol. 73, No. 18, 15.09.2013, p. 5730-5741.

Research output: Contribution to journalArticle

Yin, Y, Betsuyaku, T, Garbow, JR, Miao, J, Govindan, R & Ornitz, DM 2013, 'Rapid induction of lung adenocarcinoma by fibroblast growth factor 9 signaling through FGF receptor 3', Cancer Research, vol. 73, no. 18, pp. 5730-5741. https://doi.org/10.1158/0008-5472.CAN-13-0495
Yin, Yongjun ; Betsuyaku, Tomoko ; Garbow, Joel R. ; Miao, Jinbai ; Govindan, Ramaswamy ; Ornitz, David M. / Rapid induction of lung adenocarcinoma by fibroblast growth factor 9 signaling through FGF receptor 3. In: Cancer Research. 2013 ; Vol. 73, No. 18. pp. 5730-5741.
@article{abe6b1caa5034dd9b925b7278c1f1966,
title = "Rapid induction of lung adenocarcinoma by fibroblast growth factor 9 signaling through FGF receptor 3",
abstract = "Fibroblast growth factors (FGF) are expressed in many non-small cell lung carcinoma (NSCLC) primary tumors and derived cell lines, and mutations in FGF receptor 3 (FGFR3) have been identified in human lung adenocarcinoma. FGF9 has been implicated in the pathogenesis of NSCLC by synergizing with EGFR pathways or by providing an escape pathway mediating resistance to EGFR inhibition. To model pathogenic mechanisms mediated by FGF signals, we have established a mouse model in which FGF9 expression can be induced in adult lung epithelium. Here, we show that induced expression of FGF9 in adult lung leads to the rapid proliferation of distal airway epithelial cells that express the stem cell marker, Sca-1, and the proximal and distal epithelial markers, Sftpc and CC10, the rapid formation of Sftpc-positive adenocarcinomas, and eventual metastasis in some mice. Furthermore, we have identified FGFR3 as the obligate receptor mediating the FGF9 oncogenic signal. These results identify an FGF9-FGFR3 signal as a primary oncogenic pathway for lung adenocarcinoma and suggest that this pathway could be exploited for customized therapeutic applications for both primary tumors and those that have acquired resistance to inhibition of other signaling pathways.",
author = "Yongjun Yin and Tomoko Betsuyaku and Garbow, {Joel R.} and Jinbai Miao and Ramaswamy Govindan and Ornitz, {David M.}",
year = "2013",
month = "9",
day = "15",
doi = "10.1158/0008-5472.CAN-13-0495",
language = "English",
volume = "73",
pages = "5730--5741",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Rapid induction of lung adenocarcinoma by fibroblast growth factor 9 signaling through FGF receptor 3

AU - Yin, Yongjun

AU - Betsuyaku, Tomoko

AU - Garbow, Joel R.

AU - Miao, Jinbai

AU - Govindan, Ramaswamy

AU - Ornitz, David M.

PY - 2013/9/15

Y1 - 2013/9/15

N2 - Fibroblast growth factors (FGF) are expressed in many non-small cell lung carcinoma (NSCLC) primary tumors and derived cell lines, and mutations in FGF receptor 3 (FGFR3) have been identified in human lung adenocarcinoma. FGF9 has been implicated in the pathogenesis of NSCLC by synergizing with EGFR pathways or by providing an escape pathway mediating resistance to EGFR inhibition. To model pathogenic mechanisms mediated by FGF signals, we have established a mouse model in which FGF9 expression can be induced in adult lung epithelium. Here, we show that induced expression of FGF9 in adult lung leads to the rapid proliferation of distal airway epithelial cells that express the stem cell marker, Sca-1, and the proximal and distal epithelial markers, Sftpc and CC10, the rapid formation of Sftpc-positive adenocarcinomas, and eventual metastasis in some mice. Furthermore, we have identified FGFR3 as the obligate receptor mediating the FGF9 oncogenic signal. These results identify an FGF9-FGFR3 signal as a primary oncogenic pathway for lung adenocarcinoma and suggest that this pathway could be exploited for customized therapeutic applications for both primary tumors and those that have acquired resistance to inhibition of other signaling pathways.

AB - Fibroblast growth factors (FGF) are expressed in many non-small cell lung carcinoma (NSCLC) primary tumors and derived cell lines, and mutations in FGF receptor 3 (FGFR3) have been identified in human lung adenocarcinoma. FGF9 has been implicated in the pathogenesis of NSCLC by synergizing with EGFR pathways or by providing an escape pathway mediating resistance to EGFR inhibition. To model pathogenic mechanisms mediated by FGF signals, we have established a mouse model in which FGF9 expression can be induced in adult lung epithelium. Here, we show that induced expression of FGF9 in adult lung leads to the rapid proliferation of distal airway epithelial cells that express the stem cell marker, Sca-1, and the proximal and distal epithelial markers, Sftpc and CC10, the rapid formation of Sftpc-positive adenocarcinomas, and eventual metastasis in some mice. Furthermore, we have identified FGFR3 as the obligate receptor mediating the FGF9 oncogenic signal. These results identify an FGF9-FGFR3 signal as a primary oncogenic pathway for lung adenocarcinoma and suggest that this pathway could be exploited for customized therapeutic applications for both primary tumors and those that have acquired resistance to inhibition of other signaling pathways.

UR - http://www.scopus.com/inward/record.url?scp=84884752845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884752845&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-0495

DO - 10.1158/0008-5472.CAN-13-0495

M3 - Article

C2 - 23867472

AN - SCOPUS:84884752845

VL - 73

SP - 5730

EP - 5741

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 18

ER -